Share on LinkedInShare on LinkedIn

ARTICLE · 23 SEPTEMBER 2010

Market Definition Spurs District Court's Decisionm Denying Product Ownership Challenge

The Federal District Court in Minnesota recently decided Ovation Pharmaceutical did not violate federal or state antitrust laws when it acquired Indocin IV and NeoProfen, the only two drugs approved for treatment of a specific heart condition that primarily affects premature babies, because the challengers failed to establish that the drugs were in the same product market.

United StatesAntitrust/Competition Law
Rachael Lewis
Rachael Lewis
David Marx, Jr.
David Marx, Jr.
Author LinkedIn connections

The Federal District Court in Minnesota recently decided Ovation Pharmaceutical did not violate federal or state antitrust laws when it acquired Indocin IV and NeoProfen, the only two drugs approved for treatment of a specific heart condition that primarily affects premature babies, because the challengers failed to establish that the drugs were in the same product market. The decision raises significant issues to consider when evaluating antitrust risks in future transactions.

The U.S. District Court of the Federal District in Minnesota held that Ovation Pharmaceutical Inc. did not violate federal or state antitrust laws when it acquired Indocin IV and NeoProfen, the only two drugs approved for treatment of patent ductus arteriosus (PDA), a specific heart condition that primarily affects low-birth-weight, customarily premature babies (FTC v. Lundbeck, Inc., No. 08-6379 and Minnesota v. Lundbeck, Inc., No. 08-6381 [D. Minn. August 31, 2010]). The U.S. Federal Trade

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from